MedImmune COO retiring
Executive Summary
MedImmune Chief Operating Officer Melvin Booth will retire around end of the year, the company tells earnings call Oct. 23. "We do not have any immediate plans to fill the COO position," CEO David Mott said. Booth joined MedImmune in 1998 from Human Genome Sciences (1"The Pink Sheet" Sept. 21, 1998, In Brief)...
You may also be interested in...
Medimmune
Former Syntex Labs President Melvin Booth appointed Medimmune president and COO reporting to Chairman and CEO Wayne Hockmeyer, PhD. Booth joins Medimmune from Human Genome Sciences, where he was president
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.